peppersite
Metabolic supportsubcutaneous

Retatrutide / MOTS-c

RetatrutideMOTS-c

This is a combination of two research compounds used together rather than sold pre-mixed: retatrutide, an investigational triple receptor agonist, and MOTS-c, a peptide encoded by mitochondrial DNA. It is discussed for metabolic and body-composition research, and no published human trial has tested the pair together.

A blend, not a compound

This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.

Researched for
Metabolic HealthBody CompositionWeight ManagementMitochondrial Function

At a glance

Also called
Retatrutide + MOTS-c
Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
Sources differ. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for Retatrutide / MOTS-c, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Retatrutide / MOTS-c or for anything else, and nothing below has been checked against the study it came from.

Retatrutide: titrate 1 → 2 → 4 → 6 → 9 mg weekly (maintenance 9 mg or 12 mg weekly); MOTS-c intermittent: 5 mg 2-3x weekly (maintenance 5-10 mg 2-3x weekly); MOTS-c low-dose daily alternative: start 200 mcg/day up to 1 mg/day
Frequency
Retatrutide: once weekly; MOTS-c: 2-3x weekly (intermittent) or daily (low-dose alternative)Conservative starter: retatrutide weeks 1-24, MOTS-c weeks 5-12 then off; Standard research cycle: retatrutide weeks 1-48, MOTS-c 8-week pulses with 4-week breaks; Aggressive deficit: retatrutide weeks 1-68, MOTS-c 6 weeks on / 2 weeks off repeating
Route
subcutaneous
Reported by
peptidedosingprotocols.com
What it says[Source: peptidedosingprotocols.com]
Reconstitution, as reported
  • Standard 7-Step Reconstitution: (1) Let the lyophilized vial and BAC water reach room temperature before opening. (2) Swab both vial stoppers with alcohol and let them dry. (3) Pull the planned BAC water volume into a sterile syringe. (4) Inject the BAC water slowly down the inside of the vial wall, do not aim at the powder. (5) Swirl or roll gently until fully dissolved; do not shake. (6) Confirm the solution is clear; label the vial with compound name, concentration, and date. (7) Store at 2-8 °C; use retatrutide within 28-60 days and MOTS-c within 7 days for best potency. Each compound is reconstituted separately. Retatrutide common concentration: 10 mg vial + 1.0 mL BAC water = 10 mg/mL. MOTS-c common concentration: 10 mg vial + 2.0 mL BAC water = 5 mg/mL. MOTS-c aliquots may be stored at -20 °C for 2-3 months.
Not yet audited

We have not published an audit on Retatrutide / MOTS-c. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Retatrutide is described as cutting appetite and releasing fat from storage, while MOTS-c is described as helping muscle cells burn that fat instead of re-storing it. Researchers link MOTS-c to AMPK activation, to glucose uptake into skeletal muscle that does not depend on insulin spikes, and to reduced myostatin signalling, which may make muscle easier to hold onto. The myostatin pathway is called the most speculative of these, with limited direct human evidence, and the combination itself has not been tested in any trial.

In technical termsPairs triple incretin agonism (retatrutide) with mitochondrial signaling (MOTS-c); studied for metabolic and body-composition effects.

Reported side effects

Seen in studies: in a Phase 3 retatrutide trial, nausea was reported by 38.1 percent of participants in one arm and 43.2 percent in the higher one, dysesthesia by 8.8 to 20.9 percent depending on the arm, and 12.2 to 18.2 percent stopped treatment. Sources note that retatrutide's glucagon action produces more nausea than GLP-1-only compounds. MOTS-c safety data comes from animal work plus one early-phase human trial of the related analog CB4211.

Not ruled out: combining MOTS-c with metformin or berberine, which also act on AMPK, can lower blood glucose more than expected. The combination has not been tested in any trial, and both compounds carry the contamination risk of grey-market material.

Who should avoid it

Athletes tested under anti-doping rules: MOTS-c is WADA-prohibited, which makes the pairing unsuitable for them.

People taking metformin or berberine: these also activate AMPK, through different routes, and the overlap can lower blood glucose more than expected.

People new to either compound who have metabolic concerns: sources describe a more conservative starting approach for this group, since retatrutide is still investigational and MOTS-c is an unregulated research compound.

What gets monitored

Glucose response monitoring is named: the page states to test glucose response carefully in the early weeks if metformin or berberine is used alongside MOTS-c. A blood test (SiPhox Health At-Home Blood Test) is listed as a recommended supply. (reported by peptidedosingprotocols.com)

Common questions

Can you take MOTS-c with retatrutide?

No published human trial has tested them together. Sources describe the two as working through different mechanisms with no known direct interaction, and community protocols stagger the start rather than beginning both at once. Both can lower blood glucose, which sources flag for anyone also using metformin or berberine or training fasted.

How much MOTS-c is reported alongside retatrutide?

Reported amounts and schedules for the retatrutide and MOTS-c stack differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What amounts do sources report for taking MOTS-c with retatrutide?

Reported amounts and schedules for the retatrutide and MOTS-c stack differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Is there a pre-blended retatrutide + MOTS-c vial?

No. As of June 2026 no commercial supplier offers the two in a single pre-blended vial. Sources attribute this to their very different stability windows once mixed, with MOTS-c lasting a much shorter time refrigerated than retatrutide.

How do you reconstitute the retatrutide and MOTS-c stack?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Does MOTS-c help with muscle loss on retatrutide?

Sources describe this as the main reason researchers pair them. Preclinical evidence links MOTS-c to reduced myostatin signalling, and MOTS-c also activates AMPK in muscle and is tied to better mitochondrial function. No human trial has confirmed this for retatrutide protocols, so the case rests on mechanism plus community observation.

Is the retatrutide + MOTS-c stack safe?

Each compound has been studied on its own, but the combination has not been tested in any trial. A Phase 3 retatrutide trial reported nausea in 38.1 to 43.2 percent of participants, dysesthesia in 8.8 to 20.9 percent and discontinuation in 12.2 to 18.2 percent, while MOTS-c safety data is limited to animal studies and one analog trial. The named concerns are amplified low blood sugar, gut tolerance and contamination risk.

How long do sources run the retatrutide + MOTS-c stack?

Reported amounts and schedules for the retatrutide and MOTS-c stack differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Cagrilintide / Retatrutide

Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.

Cagrilintide / Tirzepatide

Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.

CagriSema

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.

Mazdutide

Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.

Retatrutide

Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.

Semaglutide

Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.